Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants

Advanced Drug Delivery Reviews(2021)10.1016/j.addr.2021.05.013Source: DataRank Database

Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants is a research paper published in Advanced Drug Delivery Reviews (2021). On theSindex it has a DataRank of 0. It has been cited 186 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access186 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 8.50)OA: hybridTopics (46)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Jeremiah A. Johnson ORCID,Darrell J. Irvine ORCID,Sachin Bhagchandani ORCID

Live enrichment

PubMed:34058283 PMC:PMC9003539 OpenAlex:https://openalex.org/W3164029425

NCI NIH HHS

Grant: R01 CA220468

NIAID NIH HHS

Grant: UM1 AI144462

National Institutes of Health

Grant: 3UM1AI144462-02S1

Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antivirals

National Institutes of Health

Harvard University MIT Phillip T and Susan M Ragon Institute

FWCI

8.50

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.addr.2021.05.013

publisherhttps://doi.org/10.1016/j.addr.2021.05.013

publisherhttps://api.elsevier.com/content/article/PII:S0169409X21001770?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0169409X21001770?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34058283

Fields of Study

Immune Response and InflammationImmunotherapy and Immune ResponsesImmune Cell Function and Interaction0301 basic medicine03 medical and health sciences0302 clinical medicine

MeSH Terms

Adjuvants, VaccineImmunomodulating AgentsAnimalsAntineoplastic AgentsAntiviral AgentsHumansDrug Delivery SystemsToll-Like Receptor 7Toll-Like Receptor 8

Keywords

TLR7PharmacologyBiodistributionPharmacokineticsVaccine adjuvantImmune systemMedicineToll-like receptorImmunologyInnate immune systemBiologyBiotechnologyIn vivoCancerInfectious diseaseNanoparticlesToll-like receptorsBioconjugationImmunomodulatorsVaccine AdjuvantsTlr7 AgonistsAntineoplastic AgentsAntiviral AgentsArticleImmunomodulating AgentsDrug Delivery SystemsToll-Like Receptor 7Toll-Like Receptor 8AnimalsHumansAdjuvants, Vaccine

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants

FAIR Checklist

Authors (3)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)